FDA Approval Granted for Novel Parkinson's Treatment.

DRUG therapy for Parkinson's disease; COMBINATION drug therapy; CONTROLLED release preparations; METHYLDOPA; ANTIPARKINSONIAN agents; UNITED States. Food & Drug Administration; DRUG approval; DOPA

The article reports the U.S. Food and Drug Administration's (FDA) approval of Crexont, a new Parkinson's disease treatment developed by Amneal Pharmaceuticals Incorporated, that offers extended relief of symptoms compared to existing medications. Topics discussed include the unique formulation of Crexont, the results of the Rytary in Subjects with Early PD (RISE-PD) clinical trial that supported its approval, and the expected commercial release of the drug in the U.S.